Rationale and early clinical data on IL-17 blockade in psoriasis

Steven M. Nwe, Amanda H. Champlain, Kenneth B. Gordon*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Psoriasis vulgaris is a chronic, immune-mediated, inflammatory disease that affects between 2 and 3% of the US population. Often severely physically and emotionally debilitating, psoriasis has driven investigators to strive to better characterize its complex immune pathogenesis. Some of the most promising and exciting advances have occurred in the last decade with recognition of the IL-23/Th17 pathway in disease initiation, progression and maintenance. Biologic therapies targeting various points in the pathway have met with success, prompting the study of the safety and efficacy of IL-17 blockade for moderate-to-severe plaque psoriasis. This article will review the rationale and early clinical data on IL-17 blockade in psoriasis.

Original languageEnglish (US)
Pages (from-to)677-682
Number of pages6
JournalExpert Review of Clinical Immunology
Issue number7
StatePublished - Sep 4 2013


  • IL-12/23
  • IL-17
  • Th17
  • brodalumab
  • ixekizumab
  • psoriasis vulgaris
  • secukinumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Rationale and early clinical data on IL-17 blockade in psoriasis'. Together they form a unique fingerprint.

Cite this